Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 1;13:725679. doi: 10.3389/fimmu.2022.725679

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Lin, Wang, Zheng, Gao, Huang, Chen, Xiong, Lan, Chen, Si and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Prevalence of CCND1 amplification in melanoma. (A) The prevalence of CCND1 amplification calculated using data from Chinese patients with melanoma analyzed by Geneplus (n=302) and using data from the TCGA (n=367) and MSKCC (n=350) databases. (B) The frequency of co-occurrence of CCND1 amplification with BRAF V600, NRAS, NF1, KIT in samples from Chinese patients with melanoma analyzed by Geneplus. The frequency of co-occurrence of CCND1 amplification with BRAF V600, NRAS, NF1, KIT in samples from the (C) TCGA and (D) MSKCC databases. (E) CCND1 mRNA expression in the CCND1 Neutral group (n=191), Amplification group (n=46) and High Amplification group (n=23) in samples from the TCGA database. MSKCC, the Memorial Sloan Kettering Cancer Center; TCGA, The Cancer Genome Atlas.